• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射给药时间对肿瘤摄取的影响。

Influence of the duration of intravenous drug administration on tumor uptake.

机构信息

Clinical Pharmacokinetics Department, Institut de Recherches Internationales Servier , Suresnes , France.

出版信息

Front Oncol. 2013 Jul 25;3:192. doi: 10.3389/fonc.2013.00192. eCollection 2013.

DOI:10.3389/fonc.2013.00192
PMID:23898461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3722550/
Abstract

Enhancing tumor uptake of anticancer drugs is an important therapeutic goal, because insufficient drug accumulation is now considered to be an important reason for unresponsiveness or resistance to antitumor therapy. Based on a mechanistic tumor uptake model describing tumor exposure to molecules of different molecular size after bolus administration, we have investigated the influence of the duration of intravenous administration on tumor uptake. The model integrates empirical relationships between molecular size and drug disposition (capillary permeability, interstitial diffusivity, available volume fraction, and plasma clearance), together with a compartmental pharmacokinetics model and a drug/target binding model. Numerical simulations were performed using this model for protracted intravenous drug infusion, a common mode of administration of anticancer drugs. The impact of mode of administration on tumor uptake is described for a large range of molecules of different molecular size. Evaluation was performed not only for the maximal drug concentration achieved in the tumor, but also for the dynamic profile of drug concentration. It is shown that despite a lower maximal uptake for a given dose, infusion allows for a prolonged exposure of tumor tissues to both small- and large-sized molecules. Moreover, infusion may allow higher doses to be administered by reducing Cmax-linked toxicity, thereby achieving a similar maximal uptake compared to bolus administration.

摘要

提高抗癌药物在肿瘤中的摄取量是一个重要的治疗目标,因为药物在肿瘤中的蓄积不足是导致抗肿瘤治疗无反应或耐药的一个重要原因。基于一个描述在单次静脉推注给药后肿瘤暴露于不同大小分子的机制性肿瘤摄取模型,我们研究了静脉给药持续时间对肿瘤摄取的影响。该模型综合了分子大小与药物处置(毛细血管通透性、间质扩散率、有效容积分数和血浆清除率)之间的经验关系,以及一个房室药代动力学模型和一个药物/靶标结合模型。使用该模型对常见的抗癌药物的持续静脉输注进行了数值模拟。我们描述了不同分子大小的药物在不同给药方式下对肿瘤摄取的影响。评估不仅针对肿瘤中达到的最大药物浓度,还针对药物浓度的动态变化。结果表明,尽管在给定剂量下的最大摄取量较低,但输注可以使肿瘤组织长时间暴露于小分子和大分子药物。此外,通过降低与 Cmax 相关的毒性,输注可以允许给予更高的剂量,从而与单次推注给药相比达到相似的最大摄取量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/fd012e00cf92/fonc-03-00192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/4e858bac1531/fonc-03-00192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/e89883c79228/fonc-03-00192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/fd012e00cf92/fonc-03-00192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/4e858bac1531/fonc-03-00192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/e89883c79228/fonc-03-00192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a404/3722550/fd012e00cf92/fonc-03-00192-g003.jpg

相似文献

1
Influence of the duration of intravenous drug administration on tumor uptake.静脉注射给药时间对肿瘤摄取的影响。
Front Oncol. 2013 Jul 25;3:192. doi: 10.3389/fonc.2013.00192. eCollection 2013.
2
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.一种对分子大小和结合亲和力对肿瘤靶向影响的建模分析。
Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.
3
Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.抗体亲和力和抗原密度对实体瘤中单克隆抗体摄取的预测及观察效应
Cancer Res. 1992 Jan 15;52(2):377-84.
4
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.西妥昔单抗在携带GEO人结肠癌异种移植瘤的裸鼠体内的药代动力学与抗肿瘤活性的相关性
Cancer Chemother Pharmacol. 2005 Nov;56(5):455-64. doi: 10.1007/s00280-005-1022-3. Epub 2005 Jun 10.
5
Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.通过蒙特卡洛模拟,利用健康受试者单次静脉给药后收集的药代动力学(PK)数据和群体PK建模,选择WST11的给药方案。
J Pharm Sci. 2007 Dec;96(12):3444-56. doi: 10.1002/jps.21018.
6
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.在药物产品开发中的胃肠道药物吸收的计算预测:机制吸收模型 GI-Sim 的应用。
Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29.
7
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.脂质体两性霉素B:关于其在发热性中性粒细胞减少症经验性治疗及侵袭性真菌感染治疗中应用的综述
Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010.
8
Effect of intravenous drug administration mode on drug distribution in a tumor slab: a finite Fourier transform analysis.
J Theor Biol. 1990 Mar 8;143(1):55-76. doi: 10.1016/s0022-5193(05)80288-7.
9
Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats.药代动力学特征对大鼠他克莫司胰腺毒性及疗效的影响。
J Toxicol Sci. 2008 Dec;33(5):575-84. doi: 10.2131/jts.33.575.
10
Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.基于血浆总铂测量对睾丸癌患者顺铂剂量个体化进行治疗药物监测。
Ther Drug Monit. 2006 Aug;28(4):532-9. doi: 10.1097/00007691-200608000-00008.

引用本文的文献

1
Targeting Engineered Nanoparticles for Breast Cancer Therapy.用于乳腺癌治疗的靶向工程纳米颗粒
Pharmaceutics. 2021 Nov 1;13(11):1829. doi: 10.3390/pharmaceutics13111829.
2
Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.固相肿瘤荧光引导手术中 uPAR 靶向光学成像抗体和抗体片段的并排比较。
Mol Imaging Biol. 2023 Feb;25(1):122-132. doi: 10.1007/s11307-021-01657-2. Epub 2021 Oct 12.
3
Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.

本文引用的文献

1
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.提高单克隆抗体与免疫细胞之间肿瘤积累和相互作用的方法。
MAbs. 2013 Jan-Feb;5(1):34-46. doi: 10.4161/mabs.22775. Epub 2012 Dec 4.
2
Improving drug penetration to curb tumor drug resistance.提高药物渗透以抑制肿瘤耐药性。
Drug Discov Today. 2012 Oct;17(19-20):1139-46. doi: 10.1016/j.drudis.2012.06.004. Epub 2012 Jun 15.
3
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.
通过单细胞微药物建模靶向与肿瘤组织拓扑异质性相关的配体特异性。
Sci Rep. 2018 Feb 26;8(1):3638. doi: 10.1038/s41598-018-21883-z.
4
Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization.对大小和亲和力不同的常用生物分子在肿瘤摄取和内化方面的并排比较。
PLoS One. 2015 Apr 22;10(4):e0124440. doi: 10.1371/journal.pone.0124440. eCollection 2015.
联合使用上皮连接开放剂 JO-1 可提高化疗药物的疗效和安全性。
Clin Cancer Res. 2012 Jun 15;18(12):3340-51. doi: 10.1158/1078-0432.CCR-11-3213. Epub 2012 Apr 24.
4
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.酶靶向基质消融消除了治疗胰腺导管腺癌的物理屏障。
Cancer Cell. 2012 Mar 20;21(3):418-29. doi: 10.1016/j.ccr.2012.01.007.
5
How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs.如何提高肿瘤细胞对药物的暴露程度:启动药物可增加效应药物在肿瘤中的摄取和穿透。
Adv Drug Deliv Rev. 2012 Jan;64(1):53-68. doi: 10.1016/j.addr.2011.09.007. Epub 2011 Sep 29.
6
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.针对化疗耐药的 B 系急性淋巴细胞白血病患者微小残留病灶的 T 细胞结合抗体blinatumomab 的靶向治疗可带来高缓解率和延长无白血病生存。
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
7
Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.化疗剂量方案影响卵巢癌耐药性的发展。
Mol Cancer Ther. 2011 Jul;10(7):1289-99. doi: 10.1158/1535-7163.MCT-11-0058. Epub 2011 May 6.
8
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.一种对分子大小和结合亲和力对肿瘤靶向影响的建模分析。
Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.
9
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.极低剂量的T细胞结合抗体使癌症患者肿瘤消退。
Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.
10
Drug resistance and the solid tumor microenvironment.耐药性与实体瘤微环境
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54. doi: 10.1093/jnci/djm135. Epub 2007 Sep 25.